BulgariaTuberculosis profile
Population  2014 7.2 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.15–0.16) 2.1 (2.1–2.2)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 2.3 (0.91–4.5) 33 (13–62)
Incidence  (includes HIV+TB) 1.9 (1.8–2.1) 27 (24–29)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.06 (0.05–0.06)
         
Case detection, all forms (%) 95 (87–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.3 (1.3–3.8) 23 (17–31)
MDR-TB cases among notified pulmonary
TB cases
27 (16–44) 45 (32–60)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 800   95
Pulmonary, clinically diagnosed 369   50
Extrapulmonary 481   30
       
Total new and relapse 1 825    
Previously treated, excluding relapses 47    
Total cases notified 1 872    
Among 1 825 new and relapse cases:
145 (8%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 639 (80%) 101 (45%) 740
Laboratory-confirmed RR-/MDR-TB cases     44
Patients started on MDR-TB treatment ***     29
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 377 (74)
HIV-positive TB patients 3 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT 31  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 1 903
Previously treated cases, excluding relapse, registered in 2013 (50) 2
HIV-positive TB cases, all types, registered in 2013 (75) 4
RR-/MDR-TB cases started on second-line treatment in 2012 (66) 44
XDR-TB cases started on second-line treatment in 2012 (20) 5
Laboratories 2014  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 20.8
Drug susceptibility testing (per 5 million population) 6.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 88%
% Funded internationally 12%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-04 Data: www.who.int/tb/data